None listed
Conditions
Brief summary
The study is an open study examining the effects of withdrawal of oral iron supplements in patients with the genetic condition Cystic Fibrosis (CF). In CF it is believed that unusually high levels of iron can be found in respiratory tract, and that the presence of iron within the airways may promote bacterial infection. In this study we explore how withdrawal of iron supplements may effect airway iron content and microbiology. As well as assessing the effect on systemic iron stores, lung function, and disease related symptoms. This study will be conducted by the staff of the Adult Cystic Fibrosis Centre located at The Prince Charles Hospital, Brisbane, Australia. All patients who meet the inclusion criteria will be invited to participate. Subjects will provide written informed consent prior to participation. If patients decide to withdraw from the study at any point this will not have any impact on their ongoing care.
Interventions
Patients currently prescribed oral iron supplementation who are revealed to no longer be iron deficient will have their oral iron supplements stoped, this process may be done without a need to taper.
Sponsors
Dr Daniel Smith
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Diagnosis of Cystic Fibrosis Aged Greater Than 18 years Old Competant to give written informed consent Able to Complete written questionnaires in the English Language Currently taking oral iron supllementation but with normal iron stores as indicated by a soluble transferrin receptor / Log ferritin ration of less than 1.54
Exclusion criteria
Pregnancy Current History of Malignancy Severe Symptomatic anaemia which in the opinion of the treating physicians requires ongoing iron supplementation
Outcome results
None listed